GLP-1 T (40mg)

• Composition and format
GLP-2 (40 mg) is a synthetic peptide analog supplied as a 40 mg lyophilized powder in a single vial. The batch-specific Certificate of Analysis (COA) provides sequence confirmation, net peptide content, and formulation details to support method-level reproducibility and documentation control.

• Analytical verification
Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use.

• Intended research use
GLP-2 is evaluated in controlled in-vitro systems that examine GLP-2 receptor-mediated signaling and incretin-pathway mechanisms. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes.

• Research characteristics and applications
This synthetic dual receptor agonist analog is used to explore incretin receptor signaling and endocrine communication in metabolic models. It facilitates examination of glucose-dependent signaling dynamics, receptor activation profiles, and cross-talk between GLP-2 and related incretin pathways. Its stability and receptor selectivity make it valuable for assay development, mechanistic mapping, and molecular studies of nutrient-regulated systems.

• Manufacturing and documentation
Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness.

Research Use Only (RUO) Statement
• For in-vitro research only
• Not for human or animal consumption
• Not for diagnostic or therapeutic use